‘Longevity biotech is the apotheosis of medicine’ скачать в хорошем качестве

‘Longevity biotech is the apotheosis of medicine’

Healthspan Capital’s Sebastian Brunemeier on emerging trends, technological innovations and the investment landscape in LongBio. In recent years, the field of longevity biotechnology has gained significant momentum, with myriad startups striving to develop therapies aimed at extending healthy human lifespan. Aiming to be at the forefront of this movement is Healthspan Capital, a VC firm dedicated to investing in early-stage longevity biotech – LongBio – and regenerative medicine startups. Focused on its mission to support companies that are developing therapeutics targeting aging and extending healthy human lifespan, Healthspan Capital has been one of the most active investors in the LongBio field with a whopping 32 investments in three years. The VC was founded in 2021 by a triumvirate of longevity experience – Sebastian Brunemeier (former principal at Apollo Health Ventures, the largest longevity fund in the world and cofounder at Cambrian Bio, one of the larger companies in the space), Nathan Cheng (co-Founder of the Longevity Biotech Fellowship (LBF), the largest network in the world for LongBio) and Dr Michael Chinen (an AI researcher from Google who leads the firm’s computational diligence); it distinguishes itself through a diversified investment approach, deep expertise in longevity biotech and an extensive network of collaborators, advisors and founders in the field. By investing in a broad portfolio of companies employing various approaches and modalities, the firm aims to catalyze advancements in rejuvenation biotechnology, which it believes is the future of healthspan medicine. Moreover, Healthspan Capital's rolling fund structure offers investors a flexible and straightforward way to engage in the longevity sector, making it more accessible to a wider range of stakeholders. Healthspan Capital’s impact on the longevity sector extends beyond just funding. The firm plays a pivotal role in shaping the future of longevity biotech by not only providing capital but also by leveraging its network of scientific advisors, industry leaders and entrepreneurs to drive innovation. By supporting startups that tackle the biological mechanisms of aging, Healthspan Capital is accelerating the development of therapies that could redefine healthcare – shifting the focus from treating age-related diseases to fundamentally preventing them. This proactive investment strategy not only benefits the companies within its portfolio but also helps build a robust ecosystem where scientific breakthroughs translate into real-world medical solutions. As mentioned above, one of the key figures behind Healthspan Capital is General Partner Sebastian Brunemeier, a biotech venture capitalist and company builder with a focus on longevity and regenerative medicine. Over the past five years, he has co-founded multiple longevity biotech companies, including Cambrian and Samsara Therapeutics, and we sat down with him to find out more about how Healthspan Capital and its vision is set to serve the need for more capital in the field. Find out more about Healthspan Capital: https://www.healthspancapital.vc/ Read The LongBio Report 2025: https://www.healthspancapital.vc/long... --------------------------- Visit Longevity.Technology – https://bit.ly/3PwtH8Y Follow Longevity.Technology on: Twitter - https://bit.ly/3AMIXuq Facebook - https://bit.ly/3z8H1v5 Instagram - https://bit.ly/3IDvVRX LinkedIn - https://bit.ly/3yIfDmf